VBI Vaccines (NASDAQ:VBIV) Research Coverage Started at StockNews.com
by Mitch Edgeman · The Markets DailyStockNews.com began coverage on shares of VBI Vaccines (NASDAQ:VBIV – Free Report) in a report released on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.
VBI Vaccines Stock Performance
VBI Vaccines has a 1 year low of $0.06 and a 1 year high of $1.35. The company has a 50 day simple moving average of $0.24 and a two-hundred day simple moving average of $0.49.
About VBI Vaccines
VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.
See Also
- Five stocks we like better than VBI Vaccines
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- What Does Downgrade Mean in Investing?
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- What is a Death Cross in Stocks?
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4